©The Author(s) 2026.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 114690
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114690
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114690
Table 5 Comparison of safety outcomes between the two groups, n (%)
| Group | Myelosuppression | Hepatic impairment | Renal impairment | |||||||||
| Grade I | Grade II | Grade III | Grade IV | Grade I | Grade II | Grade III | Grade IV | Grade I | Grade II | Grade III | Grade IV | |
| Integration of Chinese and Western medicine group (n = 66) | 30 | 14 | 6 | 1 | 12 | 5 | 7 | 1 | 2 | 1 | 0 | 0 |
| Western medicine group (n = 70) | 30 | 21 | 12 | 3 | 12 | 5 | 8 | 0 | 1 | 1 | 0 | 0 |
| P value | 0.003 | 0.890 | 0.631 | |||||||||
- Citation: Wang YR, Wang JQ, Chen XJ, Yan Y, Zhang Y, Li MY, Wang W, Fan TY, Jiao PF, Zhou CF. Efficacy and safety of integrated Chinese and Western medicine in advanced pancreatic cancer: A double-center retrospective cohort study. World J Gastrointest Oncol 2026; 18(2): 114690
- URL: https://www.wjgnet.com/1948-5204/full/v18/i2/114690.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.114690